Interleukin-23 Deficiency Leads to Impaired Wound Healing and Adverse Prognosis After Myocardial Infarction
Overview
Authors
Affiliations
Background: CD4+ cells are implicated in the healing process after myocardial infarction (MI). We sought to investigate the role of interleukin-23 (IL-23) deficiency, a cytokine important in differentiation of CD4+ cells, in scar formation of the ischemic heart.
Methods And Results: MI was performed in wild-type and IL23p19-/- mice. Thirty-day mortality, hemodynamic function 4 days after MI and myocardial inflammation, and remodeling 4 and 30 days after MI were examined. Differentiation of fibroblasts from infarcted and noninfarcted hearts into myofibroblasts was examined under basal conditions and after stimulation with interferon-γ, IL-17α and IL-23. Interleukin-23p19-/- mice showed higher expression of proinflammatory cytokines and immune cell infiltration in the scar early after MI compared with wild-type mice. A stronger interferon-γ/Th1 reaction seemed to be responsible for the increased inflammation under IL-23 deficiency. Expression of α-smooth muscle actin (α-SMA), collagen I and III was significantly higher in the heart tissue and isolated cardiac fibroblasts 4 days after MI in the wild-type mice. Interleukin-23p19-/- mice showed impaired healing compared with wild-type mice, as seen by significantly higher mortality because of ventricular rupture (40% higher after 30 days) and stronger left ventricular dilation early after MI. Stimulation of cardiac fibroblasts with interferon-γ, the main Th1 cytokine, but not with IL-23 or IL-17α, led to a significant downregulation of α-smooth muscle actin, collagen I and III and decreased migration and differentiation to myofibroblasts.
Conclusions: IL-23 deficiency leads to increased myocardial inflammation and decreased cardiac fibroblast activation, associated with impaired scar formation and adverse remodeling after MI.
The Roles of Exosome-Derived microRNAs in Cardiac Fibrosis.
Tang X, Leng M, Tang W, Cai Z, Yang L, Wang L Molecules. 2024; 29(6).
PMID: 38542836 PMC: 10974027. DOI: 10.3390/molecules29061199.
Bi T, Zhou Y, Mao L, Liang P, Liu J, Yang L J Tradit Complement Med. 2024; 14(1):40-54.
PMID: 38223805 PMC: 10785151. DOI: 10.1016/j.jtcme.2023.07.001.
Immunomodulation of Myocardial Fibrosis.
Sikking M, Stroeks S, Marelli-Berg F, Heymans S, Ludewig B, Verdonschot J JACC Basic Transl Sci. 2023; 8(11):1477-1488.
PMID: 38093747 PMC: 10714184. DOI: 10.1016/j.jacbts.2023.03.015.
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases.
Toldo S, Abbate A Nat Rev Cardiol. 2023; 21(4):219-237.
PMID: 37923829 PMC: 11550901. DOI: 10.1038/s41569-023-00946-3.
Tian C, Ziegler J, Zucker I Cells. 2023; 12(17).
PMID: 37681877 PMC: 10486980. DOI: 10.3390/cells12172145.